serine has been researched along with Tuberous Sclerosis in 10 studies
Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.
serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.
Tuberous Sclerosis: Autosomal dominant neurocutaneous syndrome classically characterized by MENTAL RETARDATION; EPILEPSY; and skin lesions (e.g., adenoma sebaceum and hypomelanotic macules). There is, however, considerable heterogeneity in the neurologic manifestations. It is also associated with cortical tuber and HAMARTOMAS formation throughout the body, especially the heart, kidneys, and eyes. Mutations in two loci TSC1 and TSC2 that encode hamartin and tuberin, respectively, are associated with the disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Interestingly, in certain types of cancers (e." | 1.34 | Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. ( Bernardi, R; Bonner, P; Cordon-Cardo, C; Franz, DN; Ma, L; Pandolfi, PP; Teruya-Feldstein, J; Witte, D, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dutta, R | 1 |
| Sharma, MC | 1 |
| Suri, V | 1 |
| Sarkar, C | 1 |
| Garg, A | 1 |
| Suri, A | 1 |
| Kale, SS | 1 |
| Krishnamoorthy, J | 1 |
| Tenkerian, C | 1 |
| Gupta, J | 1 |
| Ghaddar, N | 1 |
| Wang, S | 1 |
| Darini, C | 1 |
| Staschke, KA | 1 |
| Ghosh, A | 1 |
| Gandin, V | 1 |
| Topisirovic, I | 1 |
| Kristof, AS | 1 |
| Hatzoglou, M | 1 |
| Simos, G | 1 |
| Koromilas, AE | 1 |
| Madigan, JP | 1 |
| Hou, F | 1 |
| Ye, L | 1 |
| Hu, J | 1 |
| Dong, A | 1 |
| Tempel, W | 1 |
| Yohe, ME | 1 |
| Randazzo, PA | 1 |
| Jenkins, LMM | 1 |
| Gottesman, MM | 1 |
| Tong, Y | 1 |
| Di Nardo, A | 1 |
| Kramvis, I | 1 |
| Cho, N | 1 |
| Sadowski, A | 1 |
| Meikle, L | 1 |
| Kwiatkowski, DJ | 1 |
| Sahin, M | 1 |
| Li, Y | 2 |
| Inoki, K | 2 |
| Yeung, R | 1 |
| Guan, KL | 2 |
| Vacratsis, P | 1 |
| Roux, PP | 1 |
| Ballif, BA | 1 |
| Anjum, R | 1 |
| Gygi, SP | 1 |
| Blenis, J | 1 |
| Ma, L | 2 |
| Chen, Z | 1 |
| Erdjument-Bromage, H | 1 |
| Tempst, P | 1 |
| Pandolfi, PP | 2 |
| Teruya-Feldstein, J | 1 |
| Bonner, P | 1 |
| Bernardi, R | 1 |
| Franz, DN | 1 |
| Witte, D | 1 |
| Cordon-Cardo, C | 1 |
| Pipo, JR | 1 |
| Yamamoto, T | 1 |
| Takeda, H | 1 |
| Maegawa, S | 1 |
| Nanba, E | 1 |
| Ninomiya, H | 1 |
| Ohno, K | 1 |
| Takeshita, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM)[NCT03062943] | Phase 2 | 30 participants (Actual) | Interventional | 2016-12-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 other studies available for serine and Tuberous Sclerosis
| Article | Year |
|---|---|
TTF-1: A Well-Favored Addition to the Immunohistochemistry Armamentarium as a Diagnostic Marker of SEGA.
Topics: Astrocytoma; Brain Neoplasms; Child; Ependymoma; Glioblastoma; Humans; Immunohistochemistry; Neurocy | 2022 |
Downregulation of PERK activity and eIF2α serine 51 phosphorylation by mTOR complex 1 elicits pro-oxidant and pro-death effects in tuberous sclerosis-deficient cells.
Topics: Animals; Antioxidants; Cell Death; Cells, Cultured; Down-Regulation; eIF-2 Kinase; Eukaryotic Initia | 2018 |
The tuberous sclerosis complex subunit TBC1D7 is stabilized by Akt phosphorylation-mediated 14-3-3 binding.
Topics: 14-3-3 Proteins; beta-Transducin Repeat-Containing Proteins; Binding Sites; Carrier Proteins; Crysta | 2018 |
Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.
Topics: Animals; Animals, Newborn; Apoptosis; Carrier Proteins; Cells, Cultured; Child, Preschool; Dose-Resp | 2009 |
Regulation of TSC2 by 14-3-3 binding.
Topics: 14-3-3 Proteins; Adaptor Proteins, Signal Transducing; Animals; Binding Sites; Carrier Proteins; Cel | 2002 |
The p38 and MK2 kinase cascade phosphorylates tuberin, the tuberous sclerosis 2 gene product, and enhances its interaction with 14-3-3.
Topics: 14-3-3 Proteins; Amino Acid Sequence; Androstadienes; Anisomycin; Binding Sites; Culture Media, Seru | 2003 |
Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase.
Topics: Amino Acid Sequence; Animals; Cell Line; Enzyme Activation; Humans; MAP Kinase Signaling System; Mod | 2004 |
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis.
Topics: Amino Acid Sequence; Animals; Cell Line; Extracellular Signal-Regulated MAP Kinases; Humans; In Vitr | 2005 |
Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.
Topics: Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Humans; Immunoblotting; Immunoprecipita | 2007 |
Two novel serine repeat length polymorphisms (1043insS and 1043insSS) at exon 23 of the TSC1 gene.
Topics: Exons; Genes, Tumor Suppressor; Humans; Mutagenesis, Insertional; Polymorphism, Genetic; Proteins; R | 2000 |